Teva, Lilly and Amgen join battle for new $8bn migraine prevention market

New biologicals targeting the CGRP pathway could prove to be the biggest thing to hit the migraine market since the triptans in the 1990s, mid-stage data presented at the recent American Headache Society meeting in Washington suggest.